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Investigating the prevalence of anxiety and depression in people 
living with patellofemoral pain in the UK: The Dep-Pf Study 
 
ABSTRACT 1 
Background and Aims 2 
Patellofemoral pain (PFP) is a common knee condition causing pain around or behind 3 
the kneecap which is exacerbated by certain activities. Traditionally it has been viewed 4 
as a self-limiting condition. Recent research proves this is not the case and the 5 
evidence for poor long-term outcomes is growing. Whilst the evidence base for PFP 6 
treatment and the understanding of its aetiology is improving, it remains a complex and 7 
difficult to treat condition. In many physical conditions, it has been shown that anxiety 8 
and depression negatively affect both their management and duration. It is unclear how 9 
prevalent anxiety and depression are in PFP. This study aimed to identify the 10 
prevalence of anxiety and depression in people living with PFP in the UK.  11 
Methods 12 
In order to investigate this, a cross-sectional online survey was undertaken. Four 13 
hundred participants with self-reported symptoms of PFP were recruited through a 14 
tailored social media campaign, using modified snowball sampling.  Eligibility criteria 15 
were i) aged between 18 and 44, ii) self-reported symptoms of PFP (using accepted 16 
criteria) iii) resident in the UK. Exclusion criteria were previous history of patella 17 
dislocation or previous surgery to affected knee. The survey recorded demographic 18 
information, previous treatment for both PFP and anxiety and depression, the Hospital 19 
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Anxiety and Depression Scale and the Anterior Knee Pain Scale. Ethical approval was 20 
gained from a University of Plymouth Ethics Committee. 21 
Results 22 
Half (49.5%; n=198) of respondents were classified as experiencing anxiety and 20.8% 23 
(n=83) as experiencing depression. The levels of anxiety and depression identified in 24 
this study are higher than those found in the general population (5.9-7.8% and 3.3-7.8% 25 
respectively). This mirrors results which have been reported in other studies into PFP in 26 
different settings and with other musculoskeletal conditions, such as osteoarthritis and 27 
contracted shoulder.  28 
Conclusions 29 
Anxiety and depression are more common in people living with PFP than in the general 30 
population. These findings support the need for greater research into the effects of 31 
psychological factors, such as anxiety and depression, in PFP. A key area of future 32 
research will be to determine whether these psychological factors affect treatment 33 
outcomes in people living with PFP. 34 
Implications 35 
This is the first study to investigate the prevalence of anxiety and depression in people 
living with patellofemoral pain in the UK. This study shows that anxiety and depression 
are very common in people living with patellofemoral pain. The need for further work 
into the effects of psychological factors in patellofemoral pain is indicated. 
Keywords 36 




Patellofemoral pain (PFP) is a common knee condition (1) generally affecting younger 39 
and more active people (2). It is characterised by pain around or behind the patella 40 
aggravated by weight bearing activity with the knee in a flexed position (3). It has 41 
traditionally been viewed as a self-limiting condition, however more recent research has 42 
shown that over 40% of those receiving treatment for PFP will still have symptoms after 43 
a year (4) with one in four reporting ongoing pain after 20 years (5). The impact of living 44 
with PFP is becoming clear, affecting activity levels (6), social participation (7,8)  and 45 
Health related Quality of Life (8). Historically, research has focussed on the anatomical 46 
and biomechanical causes of PFP (9–11), however this is starting to change. Recently 47 
best practice guidelines have been published (12,13) which provide guidance as to the 48 
optimal management of PFP. Despite this PFP remains a complex and challenging 49 
condition to treat (14,15) and many people still continue to experience symptoms even 50 
with optimal management (4).  51 
In other musculoskeletal conditions it has been shown that anxiety and depression are 52 
more common in these populations than the general population, with figures ranging 53 
from 16-30% in those living with musculoskeletal conditions (16–18) compared with 3.3-54 
7.8% in the general UK population (19). This has led to further work to investigate the 55 
effects of psychological changes on the management and treatment of these conditions 56 
(20–22). It has been shown that increased levels of anxiety and depression are 57 
associated with greater persistence of the condition (22), increased acute pain (21), 58 
slower recovery (20) and greater risk of re-occurrence (23). Despite this there has been 59 
little work to investigate anxiety and depression in PFP (24).  60 
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A recent systematic review of psychological features in PFP (24) identified few studies 61 
investigating the prevalence of anxiety and depression with more extensive literature on 62 
the effects of kinesiophopbia and catastrophizing behaviour. Those studies which do 63 
exist reporting anxiety and depression were generally conducted with small sample 64 
sizes and using a variety of disparate outcome measures (24). This limited the ability to 65 
perform any meta-analyses to identify the true picture of anxiety and depression in PFP 66 
with only a single study (25) reporting clear prevalence figures for anxiety and 67 
depression.  Domenech et al (25) investigated the prevalence of anxiety and depression 68 
in Spanish tertiary care PFP patients. This study reported the prevalence of anxiety 69 
(30%) and depression (16%) in 97 consecutive patients attending an orthopaedic clinic. 70 
However, this is not representative of the majority of PFP patients in the UK who are 71 
managed in a primary care setting.  Attendance at an orthopaedic clinic would suggest 72 
increased severity and chronicity of the condition and, as such, these results cannot be 73 
considered representative of the general PFP population. To the best of our knowledge, 74 
there had been no UK based studies investigating anxiety and depression in people 75 
living with PFP. 76 
The aim of this study was to identify the prevalence of anxiety and depression in people 77 
living with PFP in the UK and whether there are any links between the severity of PFP 78 
and anxiety and depression. 79 
 80 
METHOD 81 
Study Design  82 
5 
 
A cross-sectional online study design was used to gain a snap-shot of the prevalence of 83 
anxiety and depression in people living with PFP in the UK population. An online 84 
approach, using Bristol Online Surveys (now Online Surveys), was used to reach a 85 
wide-ranging and diverse population which may not have been available from a more 86 
traditional outpatient centred recruitment strategy. The study was opened on 01st March 87 
2017 and closed on 09th May 2017 as the required sample size had been achieved.  88 
Participants were provided with a detailed information sheet and could withdraw at any 89 
time during or up until two weeks after completion of the survey. Ethical approval was 90 
gained from University of Plymouth Faculty of Health & Human Sciences, Schools of 91 
Medicine and Dentistry Research Ethics Committee (Reference 16/17-257) 92 
 93 
Participants 94 
A sample size of 330 was calculated, using Raosoft Sample Size calculator, based on 95 
an estimated UK population of 675,000 people living with PFP in our age range [based 96 
upon a minimum 3% prevalence (3,26), the UK population aged 15-44 (27)] and a 97 
prevalence of anxiety and depression of 30% based on the figures found by Domenech 98 
in PFP and  reported in other conditions (16–18,25). The higher figure of 30% was 99 
chosen based on the figures for anxiety (25) to reduce the risk of underpowering the 100 
study. As there is no pre-existing sampling frame participants were recruited from a variety 101 
of online sources (Facebook, Twitter, Forums, Special Interest groups, such as parkrun) 102 
who identified as having PFP based on accepted criteria (3). Recruitment was capped 103 
at 400 completed surveys. Whilst this allowed for the potential of over recruitment, this 104 
enabled people who had begun completing the survey the opportunity to complete it 105 
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once the calculated sample size was completed and to allow for any withdrawals 106 
following the closing of recruitment. Eligibility criteria were i) adults aged between 18 107 
and 44, ii) self-reported symptoms of PFP of pain when loading the knee in a flexed 108 
position, such as running, jumping, squatting, hopping (3) iii) resident in the UK. 109 
Exclusion criteria were previous history of patella dislocation or previous surgery to 110 
affected knee (3). 111 
Outcome measures 112 
A questionnaire was developed to address our research question. The data collected is 113 
summarised in Table 1. 114 
 115 
Statistical analysis 116 
Data was analysed with IBM SPSS Statistics (version 23.0). The sociodemographic 117 
characteristics of the respondents are reported as percentages and numbers. 118 
Prevalence of anxiety and depression were calculated as percentages of total sample. 119 
Independent samples t-tests were used to compare continuous variables such as age 120 
and HADS and AKPS scores. Chi-squared tests was used to compare categorical 121 
variables such as gender, previous history of anxiety and depression and duration of 122 
symptoms (categorical as grouped) with current HADS and AKPS scores. Correlation 123 
between severity of PFP symptoms (NRS and AKPS) and severity of anxiety and 124 
depression was assessed using Pearsons correlation co-efficient. Tests for normality 125 
were not run as the sample size was in excess of that required for Central Limit 126 
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Theorem assumptions of normality (28). Levels of statistical significance were set at 127 
p<0.05.  128 
RESULTS 129 
The survey was accessed 2,386 times, with 1,894 not progressing beyond the consent 130 
page and 162 people being excluded as they did not meet the inclusion criteria. The 131 
demographics of the participants are summarised in table 2, as those excluded did not 132 
complete the demographic information this is not available. Scores for the HADS-A, 133 
HADS-D, AKPS and NRS are presented in table 3. 134 
 135 
Prevalence of anxiety and depression 136 
Almost half (49.5%; n = 198) of respondents scored ≥8 on the HADS-A (29) indicating 137 
the presence of anxiety. One in five respondents (20.8%; n = 83) scored ≥8 (29) on the 138 
HADS-D indicating depressive symptoms. When combined this showed that 53% (n = 139 
215) of respondents were living with anxiety and/or depression. 140 
Age 141 
Respondents with a HADS-A score suggesting anxiety were shown to be younger than 142 
those who were not (mean age = 33.55 v 35.3) following an independent samples t-test 143 
(p= 0.015). In those with scores suggesting depressive symptoms no significant 144 





A chi-squared test for independence (with Yates’ Continuity Correction) indicated a 148 
significant association between gender and anxiety (p = 0.001). Adjusted residual 149 
scores (4.6) indicated a greater than expected number of females with anxiety. No 150 
significant association was seen between depressive symptoms and gender (p = 0.628). 151 
History of anxiety and depression 152 
A significant association between a previous diagnosis of anxiety and/or depression and 153 
a current score indicating anxiety or depressive symptoms was found using chi-154 
squared. This was found to be stronger for anxiety (phi = -0.33; p = 0.001) than 155 
depression (phi = -0.22; p = 0.001). 156 
Association with knee symptoms 157 
A significant association between AKPS score and both anxiety and depressive 158 
symptoms was identified using an independent samples t-test (Table 4). Pearson 159 
product-moment correlations showed a small negative correlation between lower scores 160 
on the AKPS and higher levels of anxiety (r = -0.15; p < 0.001), and a small to medium 161 
negative correlation between lower AKPS and higher levels of depressive symptoms (r 162 
= -0.26; p < 0.001).  163 
No significant association was identified between the NRS scores and either anxiety 164 
and depressive symptoms. 165 
Duration of Symptoms 166 
A chi-squared test identified no significant association between the duration of PFP and 167 





Until recently the role of psychological factors in PFP has received little attention. The 171 
recent publication of a systematic review (24), has emphasised the paucity of evidence 172 
in this area. The current study has suggested that over half of people living with PFP 173 
are experiencing anxiety and/or depressive symptoms. There seems to be a small 174 
correlation between increased severity of PFP symptoms (AKPS) and increased levels 175 
of anxiety and depressive symptoms. This is more marked with depressive symptoms. 176 
To the best of our knowledge this is the first study to investigate the prevalence of 177 
anxiety and depression in people living with PFP in the UK population.  178 
 179 
Anxiety and depression prevalence in PFP 180 
The levels of anxiety and depressive symptoms shown in this study are much higher 181 
than those found in the general population (anxiety: 49.5% v 5.9-7.8%; depressive 182 
symptoms 20.8 v 3.3-7.8% (19)). Whilst some caution must be exercised with these 183 
figures due to the potential for the HADS to overestimate anxiety and depression (30), 184 
and the broad inclusion criteria of the study, this suggests a significant proportion of the 185 
study population are experiencing anxiety and depression in addition to the known 186 
physical effects of PFP.  187 
Despite these concerns, the results echo those reported in other studies. Domenech et 188 
al  (25) identified similar rates of anxiety (30%) and depression (16%) in people with 189 
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PFP (n=97) in a tertiary setting. They also reported similar mean scores for HADS-A 190 
(7.9) and HADS-D (5.3). Direct comparisons with this study should be made with 191 
caution as it is not clear as to the threshold used to identify anxiety and depression. 192 
Axford et al. (18) suggested a rate of depression in excess of 40% in osteoarthritis, 193 
however this has recently been superseded by the systematic review by Stubbs et al. 194 
(16), which suggested figures of around 20% may be more accurate for both anxiety 195 
and depression in osteoarthritis. Similar figures have also been reported in contracted 196 
shoulder (17) and low back pain (31). This suggests that the findings in this study are 197 
realistic, despite concerns regarding the accuracy of the HADS as a measurement tool. 198 
The growing evidence from these studies suggest that higher levels of anxiety and 199 
depression are found across a number of MSK conditions.  200 
The figures for anxiety in this study suggest a high prevalence in people living with PFP. 201 
However, this must be viewed in the context of the study population. The study 202 
population was predominately female (67.6%) and relatively young (mean age 34.4). 203 
Previous studies have shown that anxiety is more common in younger women than in 204 
the general population (32). It must be considered whether the results found reflect the 205 
demographics of the study. Whilst there was a significant difference in the prevalence of 206 
anxiety between men and women, this alone does not explain the prevalence of anxiety 207 
in this study. 208 
Relationship between symptom severity and anxiety and depression 209 
The results of this study identified a correlation between greater severity of PFP 210 
symptoms (as measured on the AKPS) and higher scores recorded on the two elements 211 
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of the HADS. The magnitude of correlation was small for anxiety (r= - 0.15; p <0.001) 212 
and small to medium for depressive symptoms (r = -0.26; p <0.001). However the large 213 
numbers involved in this study suggest that this statistical significance may be due to 214 
the sample size (33). When we consider the strength of the relationship between the 215 
two sets of variables (-0.15 and -0.26), and the co-efficient of determination (2.25% and 216 
6.76% respectively), the low levels of these figures suggest that there is only a weak 217 
influence of the level of PFP symptoms on the level of anxiety and depressive 218 
symptoms (33). When the figures are examined the mean difference in AKPS between 219 
those with and without anxiety and depressive symptoms (Table 4), whilst statistically 220 
significant, fall well below the minimal clinically important difference for the AKPS (34).  221 
Domenech et al. (25) reported correlations of -0.61 and 0.57 for depression and anxiety 222 
(measured with the HADS) with the Lysholm score. Piva et al (35) reported a correlation 223 
of -0.45 between the KOS-ADLS and Beck Anxiety Index. This reinforces the concerns 224 
raised by Maclachlan et al. (24) regarding the heterogeneity of outcome measures used 225 
in PFP research.  It could be argued that had the current study taken a different 226 
approach to data analysis, such as a binary approach to anxiety and depression, then a 227 
stronger relationship may have been found between these factors, as suggested by 228 
previous studies. 229 
Irrespective of the magnitude of the relationships identified by Piva et al. (36), 230 
Domenech et al. (25) and the current study, all agree that there is a relationship 231 
between severity of PFP symptoms and anxiety and depression. A previous meta-232 
analysis investigating chronic pain has suggested that increased levels of depression 233 
are associated with the duration of symptoms, severity of symptoms and number of 234 
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joints affected (37). Interestingly this current study has suggested that neither the 235 
duration of symptoms nor level of pain (measured by NRS) affect the levels of anxiety 236 
and depression in PFP. This may reflect the nature of the population targeted in this 237 
study. Previous studies have concentrated on people attending a variety of secondary 238 
and tertiary healthcare settings, whereas this study has recruited people whether they 239 
were receiving formal treatment or not. PFP is not considered to be a degenerative 240 
condition, with many people having symptoms over a long time period (4,5). This may 241 
suggest that some of the respondents included in this study with long term symptoms 242 
have been managing their condition well, with pain at a low level.  243 
Future Research 244 
Further research would be beneficial to identify the effects, if any, of anxiety and 245 
depression on treatment outcomes in PFP. Should this show that anxiety and 246 
depression does have a negative impact on treatment outcomes then further studies 247 
investigating the treatment of anxiety and depression in PFP would be warranted. 248 
Whilst this study has shown that there are high levels of anxiety and depression evident 249 
in people living with PFP we are unable to draw any inferences as to why this is. Further 250 
qualitative work could identify any common themes about what contributes to the 251 
development of anxiety and depression. This could then be progressed to investigate 252 
whether there is a causative relationship between PFP and anxiety and depression and 253 
in which direction it exists. 254 
Strengths and Limitations 255 
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This study benefits from the fact we were able to over-recruit (target 330, actual 400) 256 
ensuring that we were able to adequately power all the calculations for the statistical 257 
analysis. Underpowered studies are more prone to both type I and type II errors (38) 258 
with the risk of both false positive results and ‘true’ results not reaching statistical 259 
significance. This is a weakness seen in many studies across all fields (39). The 260 
number of respondents in this study was larger than any previous study looking at 261 
mental health in PFP (24,25). 262 
The study also benefitted from using robust outcome measures (AKPS, HADS and 263 
NRS) to determine our primary outcomes (PFP severity and anxiety and depression) 264 
with good reliability and validity. These measures have been identified as the most 265 
commonly used outcome tools in PFP (24), meaning that the results of this study can be 266 
easily incorporated into any future meta-analyses.  267 
There were a number of clear limitations identified within this study. Foremost among 268 
these was the lack of clinical diagnosis for PFP amongst the respondents. Clinical 269 
assessment by an experienced clinician is considered the gold standard for diagnosis of 270 
PFP (3,12). This was not a practical option for this study due to its online nature. 271 
Instead, the criteria developed by Crossley et al. (2016) were used to classify someone 272 
as living with PFP. This raises the likelihood that other knee conditions were included in 273 
this study. The use of established inclusion and exclusion criteria should have mitigated 274 
this risk.  275 
The online nature of the study also contributed to another significant weakness within 276 
the study design. Anxiety and depression are complex, multifactorial conditions unlikely 277 
to be directly attributable to a single cause (40,41). Recent studies have also shown that 278 
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PFP is highly associated with multi-site musculoskeletal pain (42). As we were unable to 279 
collect extensive medical history for each participant we are unable to account for the 280 
effects of other musculoskeletal or chronic health conditions in this study. This limits our 281 
ability to truly say that PFP is associated with higher levels of anxiety and depression. 282 
This is shown by the high number of respondents identifying as having a history of 283 
anxiety or depression.  284 
Another limitation identified in this study is the risk of self-selection bias. Since our 285 
respondents were able to choose whether to participate in the study, it is not possible to 286 
say that this was a representative sample of the population as a whole (43). It is well 287 
established that ethnic minorities are generally under-represented in research 288 
participation (44) and that educated white females are disproportionally represented in 289 
research studies (45). This is shown in this study with an over-representation of those 290 
identifying as white (94.8%; n= 379) compared with that expected from the latest Office 291 
for National Statistics figures (86%) (46). Whilst this is a common finding across many 292 
fields of research, it raises the question about what information may be being missed in 293 
these groups. This is an area which would benefit from greater attention in future 294 
research in order to ensure a wider, and more representative, study population.  295 
CONCLUSION 296 
Anxiety and depression in people living with PFP is more common than in the general 297 
UK population. In this study almost half of people meeting the inclusion criteria for PFP 298 
had a score on the HADS-A indicating anxiety and one in five were identified as 299 
experiencing depressive symptoms on the HADS-D. To the best of our knowledge this 300 
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is the first study to investigate the prevalence of anxiety and depression of people living 301 
with PFP in the general population rather than those who are engaged in healthcare 302 
services. This study cannot draw any causal links between anxiety and depression and 303 
PFP, but it does highlight the strong association between the two conditions. The results 304 
of this study add further strength to the need for additional work into the effects of 305 
mental well-being in PFP. This is an area which has previously received little attention. 306 
  307 
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Table 1: Summary of data collected in the survey 318 
Demographics  Age 
 Gender 
 Educational level, 
 Employment status 
 Ethnicity. 
History  Duration of knee pain symptoms. 
 Any previous treatment for this. 
 Previous diagnosis of either anxiety and/or depression 
 Any current treatment for anxiety and/or depression 
Anxiety and 
Depression 
 Hospital Anxiety and Depression Scale (HADS) (47)  
 This scale gives scores for both anxiety (HADS-A) and 
depression (HADS-D) with a maximum score of 21 on each 
scale. 
 A cut-off point of ≥8 was chosen for each scale (29) . 
 Shown to have the greatest sensitivity for case detection (48).  
 The HADS has been shown to be valid and reliable for use in 
primary care, community and musculoskeletal populations 
(29,30,49,50). 
Knee symptoms  Two measures used to assess severity of PFP symptoms.  
 A numerical rating scale (NRS) for pain over the previous 24 
hours was used to assess current pain.  
 Shown to be valid and reliable in both general musculoskeletal 
conditions (51) and PFP (34). 
 Anterior Knee Pain Scale (AKPS) (52) was used to assess level 
of function.  
 Shown to be both valid and reliable in PFP patients (53) and 
requires little guidance in completion (54). 
  319 
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Table 2: Demographic data for study participants  320 
   
n 
Age, mean (SD) 34.4 (7.18) 400 
Gender - female, n (%) 268 (67.3) 397 
Ethnicity, n (%)   
White 379 (94.8) 
398 
Asian or Asian British 9 (2.3) 
Black or Black British 3 (0.8) 
Mixed / Multiple ethnic groups 5 (1.3) 
Other ethnic background 2 (0.5) 
Education, n (%)   
GCSE / O Level 26 (6.5) 
398 
AS Level 5 (1.3) 
A Level 36 (9.0) 
NVQ or other vocational 39 (9.8) 
First Degree (including foundation degree) 177 (44.3) 
University Higher Degree (Msc or PhD) 111 (27.8) 
None of the above 4 (1.0) 
Employment Status, n (%)   
Employed / Self employed 352 (88.0) 
399 
Unemployed 7 (1.8) 
Looking after home/ family 13 (3.3) 
Student / Full time education 25 (6.3) 
Unable to work 2 (0.5) 
Pain Duration, n (%)   
<3 Months 55 (13.8) 
400 
3-6 months 54 (13.5) 
6-12 months 42 (10.5) 
12-18 months 40 (10) 
18-24 months 27 (6.8) 
2-5 years 84 (21.0) 
>5 years 98 (24.5) 
Affected Knee, n (%)   
Right 111 (27.8) 
400 Left 126 (31.5) 
Both 163 (40.8) 
Previous treatment for PFP - Yes, n (%) 187 (46.8) 400 
Previous Diagnosis of anxiety or depression   
- Yes, n (%) 
136 (34.8) 400 
Receiving Treatment for anxiety or depression 
- Yes, n (%) 
45 (11.3) 400 
19 
 
Table 3: Mean values of key outcome measure for study participants. (SD = Standard deviation) 321 
Outcome Measure Mean SD 
Numerical Rating Scale - Pain 0-10, 3.45 (2.2) 
Hospital Anxiety and Depression Scale –  
Anxiety 0-21,  
7.75 (4.2) 
Hospital Anxiety and Depression Scale - 
Depression 0-21,) 
4.65 (3.5) 
Anterior Knee Pain Scale 0-100,  76.7 (10.4) 
 322 
  323 
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Table 4: Associations between anxiety and depression and key outcome measures. (NRS = Numerical Rating Scale; 324 
AKPS = Anterior Knee Pain Scale) 325 
Variable Depression Anxiety 
<8 ≥8  <8 ≥8  
(n=317) (n = 83) p (n= 202) (n = 198) p 
Age 34.40 (7.15) 34.55 (7.35) 0.86 35.30 (7.13) 33.55 (7.14) 0.015 
NRS 3.45 (2.18) 3.45 (2.35) 0.994 3.32 (2.23) 3.58 (2.19) 0.25 
AKPS 77.61 (10.23) 73.24 (10.15) 0.001 78.37 (9.96) 75 (10.49) 0.001 
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